Prognostic value of systemic inflammatory response syndrome after transcatheter aortic valve implantation.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
Systemic inflammatory response syndrome (SIRS) could affect mortality after transcatheter aortic valve implantation (TAVI) up to 12 months of follow-up. The aim of this study was to evaluate the prevalence of SIRS after TAVI and its impact on all-cause mortality up to 24 months follow-up. We retrospectively enrolled 132 patients with symptomatic severe aortic stenosis undergoing TAVI. SIRS development during the first 72 h after the intervention was evaluated. Other postoperative complications were defined according to the Valve Academic Research Consortium 2 (VARC2). All patients underwent follow-up at 30 days and 24 months. Endpoints were 30-days and 24-months mortality. Post-TAVI SIRS developed in 27 patients (20%). At 30-day follow-up, all-cause death occurred in 10 (8%) patients and SIRS occurred more frequently in patients with adverse short-term outcome (60 vs. 17%; P = 0.001). Twenty-four months all-cause death occurred in 25 (19%) patients. SIRS resulted as an independent predictor of long-term outcome [hazard ratio 3.7; 95% confidence interval (95% CI) 1.5-9; P = 0.004], along with major vascular complications (hazard ratio 4; 95% CI 1.6-9.9; P = 0.003), relevant bleedings (hazard ratio 6.4; 95% CI 1.5-28; P = 0.013) and baseline pulmonary hypertension (hazard ratio 2.4; 95% CI 1.05-5.6; P = 0.039). Postoperative SIRS was more frequent in patients who died at 30 days follow-up. Moreover, SIRS resulted as a predictor of 24-month mortality along with vascular complications, relevant bleedings and baseline pulmonary hypertension.
Identifiants
pubmed: 35645030
doi: 10.2459/JCM.0000000000001309
pii: 01244665-202206000-00007
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
394-398Informations de copyright
Copyright © 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Güvener M, Korun O, Demirtürk OS. Risk factors for systemic inflammatory response after congenital cardiac surgery. J Card Surg 2015; 30:92–96.
Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:1243–1253.
Squiccimarro E, Labriola C, Malvindi PG, et al. Prevalence and clinical impact of systemic inflammatory reaction after cardiac surgery. J Cardiothorac Vasc Anesth 2019; 33:1682–1690.
Sinning JM, Scheer AC, Adenauer V, et al. Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J 2012; 33:1459–1468.
Lindman BR, Goldstein JS, Nassif ME, et al. Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement. Heart 2015; 101:537–545.
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. 1992; Chest: Elsevier, 1644–1655.
Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:801–810.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document (varc-2). Eur J CardiothoracW Surg 2012; 42:
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:2739–2786.
Klein AL, Abbara S, Agler DA, et al. American society of echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the society for cardiovascular magnetic resonance and society of cardiovascular computed tomography. J Am Soc Echocardiogr 2013; 26:965–1012. e15.
Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J 2015; 36:2921–2964.
Gorla R, Erbel R, Eagle KA, Bossone E. Systemic inflammatory response syndromes in the era of interventional cardiology. Vasc Pharmacol 2018; 107:53--66.
Rettig TCD, Rigter S, Nijenhuis VJ, et al. The systemic inflammatory response syndrome predicts short-term outcome after transapical transcatheter aortic valve implantation. J Cardiothorac Vasc Anesth 2015; 29:283–287.
Hoffmann J, Mas-Peiro S, Berkowitsch A, et al. Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation. ESC Hear Fail 2020; 7:2597–2610.
Erdoes G, Lippuner C, Kocsis I, et al. Technical approach determines inflammatory response after surgical and transcatheter aortic valve replacement. PLoS One 2015; 10:1–14.
Jansen F, Rohwer K, Vasa-Nicotera M, et al. CD-144 positive endothelial microparticles are increased in patients with systemic inflammatory response syndrome after TAVI. Int J Cardiol 2016; 204:172–174.
Imazio M, Hoit BD. Review: postcardiac injury syndromes. An emerging cause of pericardial diseases. Int J Cardiol 2013; 168:648–652.
Schwietz T, Behjati S, Gafoor S, et al. Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon- and self-expandable valves. EuroIntervention 2015; 10:1468–1473.
Sexton TR, Wallace EL, Chen A, et al. Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement. J Thromb Thrombolysis 2016; 41:384–393.
Sinning JM, Ghanem A, Steinhuser H, et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv 2010; 3:1141–1149.
Havakuk O, Konigstein M, Ben Assa E, et al. Steroid therapy and conduction disturbances after transcatheter aortic valve implantation. Cardiovasc Ther 2016; 34:325–329.